Literature DB >> 31189703

Retrograde Regulation by the Viral Protein Kinase Epigenetically Sustains the Epstein-Barr Virus Latency-to-Lytic Switch To Augment Virus Production.

Xiaofan Li1, Sergei V Kozlov2, Ayman El-Guindy3, Sumita Bhaduri-McIntosh4,5.   

Abstract

Herpesviruses are ubiquitous, and infection by some, like Epstein-Barr virus (EBV), is nearly universal. To persist, EBV must periodically switch from a latent to a replicative/lytic phase. This productive phase is responsible for most herpesvirus-associated diseases. EBV encodes a latency-to-lytic switch protein which, upon activation, sets off a vectorially constrained cascade of gene expression that results in production of infectious virus. While triggering expression of the switch protein ZEBRA is essential to lytic cycle entry, sustaining its expression is equally important to avoid premature termination of the lytic cascade. We report that the viral protein kinase (vPK), encoded by a gene that is kinetically downstream of the lytic switch, sustains expression of ZEBRA, amplifies the lytic cascade, increasing virus production, and, importantly, prevents the abortive lytic cycle. We find that vPK, through a noncanonical site phosphorylation, activates the cellular phosphatidylinositol 3-kinase-related kinase ATM to cause phosphorylation of the heterochromatin enforcer KAP1/TRIM28 even in the absence of EBV genomes or other EBV proteins. Phosphorylation of KAP1 renders it unable to restrain ZEBRA, thereby further derepressing and sustaining its expression to culminate in virus production. This partnership with a host kinase and a transcriptional corepressor enables retrograde regulation by vPK of ZEBRA, an observation that is counter to the unidirectional regulation of gene expression reminiscent of most DNA viruses.IMPORTANCE Herpesviruses infect nearly all humans and persist quiescently for the life of the host. These viruses intermittently activate into the lytic phase to produce infectious virus, thereby causing disease. To ensure that lytic activation is not prematurely terminated, expression of the virally encoded lytic switch protein needs to be sustained. In studying Epstein-Barr virus, one of the most prevalent human herpesviruses that also causes cancer, we have discovered that a viral kinase activated by the viral lytic switch protein partners with a cellular kinase to deactivate a silencer of the lytic switch protein, thereby providing a positive feedback loop to ensure successful completion of the viral productive phase. Our findings highlight key nodes of interaction between the host and virus that could be exploited to treat lytic phase-associated diseases by terminating the lytic phase or kill cancer cells harboring herpesviruses by accelerating the completion of the lytic cascade.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  epigenetics; human herpesviruses; lytic activation; viral protein kinase

Mesh:

Substances:

Year:  2019        PMID: 31189703      PMCID: PMC6694827          DOI: 10.1128/JVI.00572-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Protein detection using proximity-dependent DNA ligation assays.

Authors:  Simon Fredriksson; Mats Gullberg; Jonas Jarvius; Charlotta Olsson; Kristian Pietras; Sigrún Margrét Gústafsdóttir; Arne Ostman; Ulf Landegren
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

2.  Promoter sequences required for reactivation of Epstein-Barr virus from latency.

Authors:  Ulrich K Binné; Wolfgang Amon; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Authors:  M R Chen; S J Chang; H Huang; J Y Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment.

Authors:  Ayumi Kudoh; Masatoshi Fujita; Lumin Zhang; Noriko Shirata; Tohru Daikoku; Yutaka Sugaya; Hiroki Isomura; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2004-12-15       Impact factor: 5.157

5.  Role of the epstein-barr virus RTA protein in activation of distinct classes of viral lytic cycle genes.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice.

Authors:  Charles H Cook; Yingxue Zhang; Brian J McGuinness; Michael C Lahm; Daniel D Sedmak; Ronald M Ferguson
Journal:  J Infect Dis       Date:  2002-04-30       Impact factor: 5.226

7.  The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1.

Authors:  Gregory K Hong; Henri-Jacques Delecluse; Henri Gruffat; Thomas E Morrison; Wen-Hai Feng; Alain Sergeant; Shannon C Kenney
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation.

Authors:  Christopher J Bakkenist; Michael B Kastan
Journal:  Nature       Date:  2003-01-30       Impact factor: 49.962

9.  Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia.

Authors:  N M Sawtell; R L Thompson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Identification of protein kinases responsible for phosphorylation of Epstein-Barr virus nuclear antigen leader protein at serine-35, which regulates its coactivator function.

Authors:  Kentaro Kato; Akihiko Yokoyama; Yukinobu Tohya; Hiroomi Akashi; Yukihiro Nishiyama; Yasushi Kawaguchi
Journal:  J Gen Virol       Date:  2003-12       Impact factor: 3.891

View more
  8 in total

1.  A promiscuous inflammasome sparks replication of a common tumor virus.

Authors:  Eric M Burton; Raphaela Goldbach-Mansky; Sumita Bhaduri-McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-09       Impact factor: 11.205

2.  KAP1 phosphorylation promotes the survival of neural stem cells after ischemia/reperfusion by maintaining the stability of PCNA.

Authors:  Wan Wang; Tianqing Yan; Xinjian Guo; Heng Cai; Chang Liang; Linyan Huang; Yanling Wang; Ping Ma; Suhua Qi
Journal:  Stem Cell Res Ther       Date:  2022-07-07       Impact factor: 8.079

3.  An Ancestral Retrovirus Envelope Protein Regulates Persistent Gammaherpesvirus Lifecycles.

Authors:  Tiffany R Frey; Ibukun A Akinyemi; Eric M Burton; Sumita Bhaduri-McIntosh; Michael T McIntosh
Journal:  Front Microbiol       Date:  2021-08-09       Impact factor: 6.064

4.  A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.

Authors:  Xiaofan Li; Ibukun A Akinyemi; Jeehyun Karen You; Mohammad Ali Rezaei; Chenglong Li; Michael T McIntosh; Maurizio Del Poeta; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

5.  A heterochromatin inducing protein differentially recognizes self versus foreign genomes.

Authors:  Eric M Burton; Ibukun A Akinyemi; Tiffany R Frey; Huanzhou Xu; Xiaofan Li; Lai Jing Su; Jizu Zhi; Michael T McIntosh; Sumita Bhaduri-McIntosh
Journal:  PLoS Pathog       Date:  2021-03-17       Impact factor: 6.823

Review 6.  KAP1/TRIM28: Transcriptional Activator and/or Repressor of Viral and Cellular Programs?

Authors:  Keyera Randolph; Usman Hyder; Iván D'Orso
Journal:  Front Cell Infect Microbiol       Date:  2022-02-23       Impact factor: 6.073

7.  Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.

Authors:  Yuchen Zhang; Chang Jiang; Stephen J Trudeau; Yohei Narita; Bo Zhao; Mingxiang Teng; Rui Guo; Benjamin E Gewurz
Journal:  mBio       Date:  2020-10-27       Impact factor: 7.867

Review 8.  Inflammasome, the Constitutive Heterochromatin Machinery, and Replication of an Oncogenic Herpesvirus.

Authors:  Sumita Bhaduri-McIntosh; Michael T McIntosh
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.